[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570200":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":101,"collaborators":25,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":25,"eligibilityCriteria":109,"healthyVolunteers":105,"sex":110,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":25,"studyType":116,"phases":117,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"BlueSphere Bio, Inc","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation Cohorts","EXPERIMENTAL","AML, ALL and MDS HLA-A\\*02:01 and HA-1-positive (H\u002FH or H\u002FR) patients with an identified HLA-matched, HA-1-negative (R\u002FR) donor will be dosed in dose escalation cohorts",[13],"Drug: SOC + BSB-1001 Dose Escalation Cohort",{"label":15,"type":10,"description":16,"interventionNames":17},"BSB-1001 Expansion Dose","Once the maximum tolerated dose (MTD) or promising dose is reached additional AML HLA-A\\*02:01 and HA-1-positive (H\u002FH or H\u002FR) patients with an identified HLA-matched, HA-1-negative (R\u002FR) donor will be enrolled in the expansion cohort.",[18],"Drug: SOC+BSB-1001 Expansion Dose",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","SOC + BSB-1001 Dose Escalation Cohort","Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic stem cell transplant (HCT).",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"SOC+BSB-1001 Expansion Dose","Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic cell transplant (HCT).",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Medical Director: Nawazish Khan, MD, BlueSphere Bio","CONTACT","252-347-4938","nkhan@bluespherebio.com",[37,51,61,71,81,91],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":25},"City of Hope National Medical Center","RECRUITING","Duarte","California","91010","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-117.97729,34.13945,{"lat":49,"lon":48},{"facility":52,"status":39,"city":53,"state":54,"zip":55,"country":43,"countryCode":44,"cosmosGeoPoint":56,"geoPoint":60,"contacts":25},"Moffitt Cancer Center","Tampa","Florida","33612",{"type":46,"coordinates":57},[58,59],-82.45843,27.94752,{"lat":59,"lon":58},{"facility":62,"status":39,"city":63,"state":64,"zip":65,"country":43,"countryCode":44,"cosmosGeoPoint":66,"geoPoint":70,"contacts":25},"University of Michigan","Ann Arbor","Michigan","48109",{"type":46,"coordinates":67},[68,69],-83.74088,42.27756,{"lat":69,"lon":68},{"facility":72,"status":39,"city":73,"state":74,"zip":75,"country":43,"countryCode":44,"cosmosGeoPoint":76,"geoPoint":80,"contacts":25},"University of Minnesota","Minneapolis","Minnesota","55455",{"type":46,"coordinates":77},[78,79],-93.26384,44.97997,{"lat":79,"lon":78},{"facility":82,"status":39,"city":83,"state":84,"zip":85,"country":43,"countryCode":44,"cosmosGeoPoint":86,"geoPoint":90,"contacts":25},"Washington University at St Louis","St Louis","Missouri","63110",{"type":46,"coordinates":87},[88,89],-90.19789,38.62727,{"lat":89,"lon":88},{"facility":92,"status":39,"city":93,"state":94,"zip":95,"country":43,"countryCode":44,"cosmosGeoPoint":96,"geoPoint":100,"contacts":25},"The Ohio State University","Columbus","Ohio","43210",{"type":46,"coordinates":97},[98,99],-82.99879,39.96118,{"lat":99,"lon":98},{"type":102,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100570200","phase-1-bsb-1001-in-patients-undergoing-hla-matched-allogenic-hematopoietic-stem-cell-transplant-for-aml-all-or-mds-100570200",false,"NCT06704152","BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS","A Phase 1\u002F2a Multicenter Ascending Dose Study to Evaluate the Safety of HA-1 Minor Histocompatibility Antigen-Reactive TCR-Modified T Cells (BSB-1001) in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS","Inclusion Criteria:\n\n1. Male or female patients, ages 18 - 70 years inclusive, undergoing alloHCT.\n2. Any of the following high-risk hematologic malignancies:\n\n   1. AML diagnosed which has been treated with at least two lines of therapy\\* Refractory or relapsed (CR, CRh or CRi,), including myeloblasts up to 25% OR MRD positive OR persistent disease-defining cytogenetic abnormality OR MRD-negative, but with high-risk disease For patients in remission meeting criteria a, consolidation regimens would be considered another line of therapy of eligibility purposes\n   2. ALL which has been with abnormal lymphoblasts ≥5% and up to 25% in bone marrow OR persistent disease-defining cytogenetic abnormality or MRD positive\n   3. MDS after at least one line of therapy, which includes hypomethylating agent(s) and must be high or very high risk by Revised International Prognostic Scoring System (IPSS-R), monosomy, or complex karyotype or TP53 mutation.\n   4. In the expansion phase AML patients diagnosed which has been treated with at least two lines of therapy, and refractory or relapsed (CR, CRh or CRi,), including myeloblasts up to 25% OR MRD positive OR persistent disease-defining cytogenetic abnormality OR MRD-negative, but with high- risk disease\n3. HLA-A\\*02:01 AND HA-1 positive (either H\u002FH or H\u002FR).\n4. Suitable for one of the approved conditioning regimens as defined in the protocol.\n5. Patient must have an identified donor that is HA 1-negative with 10\u002F10 matched related or unrelated donor\n\nExclusion Criteria:\n\n1. Weight \\> 100 kg.\n2. Prior history of allogeneic stem cell transplantation\n3. Prior history of autologous stem cell transplantation within 1 year prior to the planned dosing of BSB-1001 (day 0)\n4. Previous genetically engineered chimeric antigen receptor T Cell therapy (CAR-T), approved or investigational, within 2 years of screening, with the exception of patients with ALL previously treated with an autologous CAR-T product.\n5. Treatment with other investigational agents within 5 half-lives of the planned dosing of BSB-1001 (day 0).\n6. History of treatment with checkpoint inhibitor therapy within 3 months of transplantation.\n7. Other malignancy with life expectancy \\\u003C 1year.\n8. Pregnant or lactating women.\n9. Uncontrolled bacterial, viral, or fungal infections at time of enrollment.\n10. Past or current viral infections as defined in the protocol.\n11. CNS involvement refractory to intrathecal chemotherapy and\u002For standard cranial- spinal radiation. 12 Karnofsky Performance Score \\\u003C 60%.\n\n13\\. Inadequate organ function as defined in protocol.","ALL","18 Years","70 Years",{"count":114,"type":115},38,"ESTIMATED","INTERVENTIONAL",[118,119],"PHASE1","PHASE2","The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.",[122,123,124],"AML, Adult Recurrent","ALL, Recurrent, Adult","MDS",[126],"TCR, T-cell therapy","2025-09-17",{"date":129,"type":130},"2025-09-18","ACTUAL",{"date":132,"type":130},"2025-02-04",{"date":134,"type":115},"2029-03",{"name":5,"class":6},6]